160 related articles for article (PubMed ID: 23928249)
41. Imaging in breast cancer: Magnetic resonance spectroscopy.
Bolan PJ; Nelson MT; Yee D; Garwood M
Breast Cancer Res; 2005; 7(4):149-52. PubMed ID: 15987466
[TBL] [Abstract][Full Text] [Related]
42. Metabolic characterization of primary and metastatic ovarian cancer by 1H-MRS in vivo at 3T.
McLean MA; Priest AN; Joubert I; Lomas DJ; Kataoka MY; Earl H; Crawford R; Brenton JD; Griffiths JR; Sala E
Magn Reson Med; 2009 Oct; 62(4):855-61. PubMed ID: 19645005
[TBL] [Abstract][Full Text] [Related]
43. MR spectroscopy in the breast clinic is improving.
Mountford CE; Schuster C; Baltzer PA; Malycha P; Kaiser WA
Eur J Radiol; 2012 Sep; 81 Suppl 1():S104-6. PubMed ID: 23083547
[No Abstract] [Full Text] [Related]
44. Three-dimensional proton MR spectroscopic imaging at 3 T for the differentiation of benign and malignant breast lesions.
Gruber S; Debski BK; Pinker K; Chmelik M; Grabner G; Helbich T; Trattnig S; Bogner W
Radiology; 2011 Dec; 261(3):752-61. PubMed ID: 21998046
[TBL] [Abstract][Full Text] [Related]
45. In vivo MRS of locally advanced breast cancer: characteristics related to negative or positive choline detection and early monitoring of treatment response.
Bathen TF; Heldahl MG; Sitter B; Vettukattil R; Bofin A; Lundgren S; Gribbestad IS
MAGMA; 2011 Dec; 24(6):347-57. PubMed ID: 21909791
[TBL] [Abstract][Full Text] [Related]
46. Noninvasive evaluation of cerebral glioma grade by using multivoxel 3D proton MR spectroscopy.
Zeng Q; Liu H; Zhang K; Li C; Zhou G
Magn Reson Imaging; 2011 Jan; 29(1):25-31. PubMed ID: 20832225
[TBL] [Abstract][Full Text] [Related]
47. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models.
Al-Saffar NM; Troy H; Ramírez de Molina A; Jackson LE; Madhu B; Griffiths JR; Leach MO; Workman P; Lacal JC; Judson IR; Chung YL
Cancer Res; 2006 Jan; 66(1):427-34. PubMed ID: 16397258
[TBL] [Abstract][Full Text] [Related]
48. Preliminary study of 3T 1H MR spectroscopy in bone and soft tissue tumors.
Qi ZH; Li CF; Li ZF; Zhang K; Wang Q; Yu DX
Chin Med J (Engl); 2009 Jan; 122(1):39-43. PubMed ID: 19187615
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of single voxel 1H MR spectroscopic imaging at 3T for the differentiation of benign and malign breast lesions.
Ramazan A; Demircioglu O; Ugurlu U; Kaya H; Aribal E
Clin Imaging; 2016; 40(5):831-6. PubMed ID: 27179154
[TBL] [Abstract][Full Text] [Related]
50. MR spectroscopy of the breast.
Sardanelli F; Fausto A; Podo F
Radiol Med; 2008 Feb; 113(1):56-64. PubMed ID: 18338127
[TBL] [Abstract][Full Text] [Related]
51. Clinical evaluation of choline measurement by proton MR spectroscopy in patients with malignant tumors.
Lee J; Yamaguchi T; Abe A; Shizukuishi K; Uemura H; Miyagi E; Sakata K; Inoue T
Radiat Med; 2004; 22(3):148-54. PubMed ID: 15287529
[TBL] [Abstract][Full Text] [Related]
52. Characterisation of in vivo ovarian cancer models by quantitative 1H magnetic resonance spectroscopy and diffusion-weighted imaging.
Canese R; Pisanu ME; Mezzanzanica D; Ricci A; Paris L; Bagnoli M; Valeri B; Spada M; Venditti M; Cesolini A; Rodomonte A; Giannini M; Canevari S; Podo F; Iorio E
NMR Biomed; 2012 Apr; 25(4):632-42. PubMed ID: 22020805
[TBL] [Abstract][Full Text] [Related]
53. Monitoring of early response to neoadjuvant chemotherapy in breast cancer with (1)H MR spectroscopy: comparison to sequential 2-[18F]-fluorodeoxyglucose positron emission tomography.
Tozaki M; Sakamoto M; Oyama Y; O'uchi T; Kawano N; Suzuki T; Yamashiro N; Ozaki S; Sakamoto N; Higa K; Abe S; Ogawa T; Fukuma E
J Magn Reson Imaging; 2008 Aug; 28(2):420-7. PubMed ID: 18666159
[TBL] [Abstract][Full Text] [Related]
54. Monitoring the therapeutic response of locally advanced breast cancer patients: sequential in vivo proton MR spectroscopy study.
Kumar M; Jagannathan NR; Seenu V; Dwivedi SN; Julka PK; Rath GK
J Magn Reson Imaging; 2006 Aug; 24(2):325-32. PubMed ID: 16786567
[TBL] [Abstract][Full Text] [Related]
55. In vivo detection of choline in ovarian tumors using 3D magnetic resonance spectroscopy.
Esseridou A; Di Leo G; Sconfienza LM; Caldiera V; Raspagliesi F; Grijuela B; Hanozet F; Podo F; Sardanelli F
Invest Radiol; 2011 Jun; 46(6):377-82. PubMed ID: 21467947
[TBL] [Abstract][Full Text] [Related]
56. Multimodal assessment of early tumor response to chemotherapy: comparison between diffusion-weighted MRI, 1H-MR spectroscopy of choline and USPIO particles targeted at cell death.
Radermacher KA; Magat J; Bouzin C; Laurent S; Dresselaers T; Himmelreich U; Boutry S; Mahieu I; Vander Elst L; Feron O; Muller RN; Jordan BF; Gallez B
NMR Biomed; 2012 Apr; 25(4):514-22. PubMed ID: 21874657
[TBL] [Abstract][Full Text] [Related]
57. Investigation of breast cancer using two-dimensional MRS.
Thomas MA; Lipnick S; Velan SS; Liu X; Banakar S; Binesh N; Ramadan S; Ambrosio A; Raylman RR; Sayre J; DeBruhl N; Bassett L
NMR Biomed; 2009 Jan; 22(1):77-91. PubMed ID: 19086016
[TBL] [Abstract][Full Text] [Related]
58. In vivo 1H-MRS evaluation of malignant and benign breast diseases.
Kim JK; Park SH; Lee HM; Lee YH; Sung NK; Chung DS; Kim OD
Breast; 2003 Jun; 12(3):179-82. PubMed ID: 14659324
[TBL] [Abstract][Full Text] [Related]
59. Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy.
Sitter B; Bathen TF; Singstad TE; Fjøsne HE; Lundgren S; Halgunset J; Gribbestad IS
NMR Biomed; 2010 May; 23(4):424-31. PubMed ID: 20101607
[TBL] [Abstract][Full Text] [Related]
60. Metabolite quantification and high-field MRS in breast cancer.
Haddadin IS; McIntosh A; Meisamy S; Corum C; Styczynski Snyder AL; Powell NJ; Nelson MT; Yee D; Garwood M; Bolan PJ
NMR Biomed; 2009 Jan; 22(1):65-76. PubMed ID: 17957820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
